Abstract 4228
Background
Lipiodol transcatheter arterial chemoembolization (TACE) , known as c-TACE , is widely used to treat hepatocellular carcinoma (HCC). Recently, a drug-eluting bead (DEB) has been developed to sustain continual drug delivery to the tumor. We evaluate the efficacy and safety of TACE with doxorubicin-loaded drug eluting beads (D-TACE) in this study.
Methods
This retrospective study included 228 unresectable HCC patients who received cTACE (n = 153) or D-TACE(n = 75) in Zhongshan hospital, Fudan University from September 2018 to February 2019. Tumor response were evaluated by MRI according mRECIST one month after treatment, and adverse events were recorded as well.
Results
The disease control rate(DCR) of D-TACE was 78.6% versus 49.3% of c-TACE(p = 0.03),which demonstrated D-TACE had the better tumor reponse. There were no treatment related major complications in all patients, and no statistically significant difference in postembolization syndrome , liver toxicity and hematological toxicity between two groups(p > 0.05). Subgroup analyses indicated that patients with tumor size less than 7cm and tumor numbers less than 3 favored D-TACE , while there was no significant difference in efficacy in the patients with tumor size greater than 10cm (P > 0.05).
Conclusions
In unresectable HCC, transcatheter treatment with DEB loaded with doxorubicin offers a better objective tumor response than conventional TACE, especially in patients with tumor size less than 7cm and tumor numbers less than 3.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract
4761 - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment
Presenter: Joana Simões
Session: Poster Display session 1
Resources:
Abstract